21th Scientific Congress of BgDA


Updates on medication - Related osteonecrosis of the jaws


 Medication-related osteonecrosis of the jaws (MRONJ) is a severe complication that manifests with many possible clinical signs and symptoms, including exposed bone, fistula, inflammation with or without suppuration, ulcers, soft and hard tissue necrosis, and edema. In the majority of cases, MRONJ manifests as exposed bone in the maxillofacial region, although non-exposed MRONJ has also been recognized


 MRONJ is a drug-related complication, observed in patients receiving mainly agents with antiresorptive and antiangiogenic properties. 


Since the first cases of MRONJ were reported, significant progress has been made in understanding the pathophysiology of the disease but still the pathophysiology of MRONJ has not been fully clarified. Different hypotheses have been proposed to explain the pathogenesis of this complication.


The primary parameter to be considered for the development of MRONJ, is the therapeutic indication for treatment (eg, malignancy or osteoporosis/osteopenia). The etiology of MRONJ is multifactorial as a result of the association of metabolic, local and genetic factors. The most reported dental risk factor is tooth extraction, followed by periodontal disease while chemotherapy and corticosteroids are the most frequently reported medical risk factors. 


Staging and treatment guidelines have been proposed however, there has been no universal acceptance, and clinicians rely on various position papers. The major treatment objectives for patients with MRONJ are pain and infection control and minimization of ONJ progression. Strategies for management of patients at risk for or with MRONJ will be discussed.


The lecture aims to provide an update regarding definition, staging, pathophysiology, risk factors and treatment strategies of medication-related osteonecrosis of the jaws.


 

Dr. Emmanouil Vardas

Dr. Emmanouil Vardas


 Mr. Emmanouil Vardas received his DDS degree, having graduated from the School of Dentistry of National and Kapodistrian University of Athens Greece (NKUA) in 1992. After his graduation he completed his Master of Science Degree in Oral Pathology at School of Dentistry NKUA and his Master of Science Degree in Advanced General Dental Practice at King’s College of London UK in 2000 and 2014 respectively. He received his Phd Degree at School of Dentistry of NKUA in 2009. He was appointed as Assistant Professor at the Department of Oral Pathology & Hospital Dentistry - Dental Oncology Unit at School of Dentistry of NKUA in 2019. He is the general secretary of the Dental Association of Athens Greece (Member of the Board & scientific committee) and also member of the Board of the Hellenic Dental Association, member of the European Association of Oral Medicine and member in many Hellenic and International Scientific Societies. His fields of scientific interests include medication related osteonecrosis of the jaws, oral complications in cancer therapies, oral care in cancer and quality of life in cancer. He has undertaken a large number of presentations in Hellenic and International Congresses and he has published scientific work in Hellenic and International scientific journals.


back to 21th Scientific Congress of BgDA